{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:05:22Z","timestamp":1772111122946,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,4,12]],"date-time":"2006-04-12T00:00:00Z","timestamp":1144800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2006,5,11]]},"DOI":"10.1007\/s00198-006-0085-2","type":"journal-article","created":{"date-parts":[[2006,4,11]],"date-time":"2006-04-11T16:44:32Z","timestamp":1144773872000},"page":"922-928","source":"Crossref","is-referenced-by-count":120,"title":["Persistence with weekly alendronate therapy among postmenopausal women"],"prefix":"10.1007","volume":"17","author":[{"given":"J. C.","family":"Lo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. R.","family":"Pressman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Omar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Ettinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,4,12]]},"reference":[{"key":"85_CR1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"85_CR2","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"IC Chesnut","year":"2004","unstructured":"Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"85_CR3","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"85_CR4","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"85_CR5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"85_CR6","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003\u20131008","journal-title":"Osteoporos Int"},{"key":"85_CR7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.maturitas.2004.02.005","volume":"48","author":"JS McCombs","year":"2004","unstructured":"McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271\u2013287","journal-title":"Maturitas"},{"key":"85_CR8","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00198-003-1502-4","volume":"14","author":"RA Yood","year":"2003","unstructured":"Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965\u2013968","journal-title":"Osteoporos Int"},{"key":"85_CR9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","volume":"89","author":"JA Clowes","year":"2004","unstructured":"Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117\u20131123","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"85_CR10","first-page":"S398","volume":"20","author":"B Ettinger","year":"2005","unstructured":"Ettinger B, Earnshaw SR, Graham CN, Amonkar MM, Baran RW (2005) Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: Implications of improved persistence with ibandronate. J Bone Miner Res 20(Suppl 1):S398\u2013S399 (abstract M361)","journal-title":"J Bone Miner Res"},{"key":"85_CR11","volume-title":"MEDSTAT Group Inc.","author":"MarketScan","year":"2000","unstructured":"MarketScan (2000) MEDSTAT Group Inc. Ann Arbor, MI"},{"key":"85_CR12","first-page":"449","volume":"11","author":"R Sikka","year":"2005","unstructured":"Sikka R, Xia F, Aubert RE (2005) Estimating medication persistency using administrative claims data. Am J Manag Care 11:449\u2013457","journal-title":"Am J Manag Care"},{"key":"85_CR13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2105\/AJPH.82.5.703","volume":"82","author":"N Krieger","year":"1992","unstructured":"Krieger N (1992) Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 82:703\u2013710","journal-title":"Am J Public Health"},{"key":"85_CR14","first-page":"S207","volume":"10","author":"RG Miller","year":"2004","unstructured":"Miller RG, Bolognese M, Worley K, Solis A, Sheer R (2004) Incidence of gastrointestinal events among bisphosphonate patients in an observational setting. Am J Manag Care 10:S207\u2013S215","journal-title":"Am J Manag Care"},{"key":"85_CR15","first-page":"597","volume":"7","author":"B Ettinger","year":"2001","unstructured":"Ettinger B, Chidambaran P, Pressman A (2001) Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manag Care 7:597\u2013605","journal-title":"Am J Manag Care"},{"key":"85_CR16","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1185\/030079905X61875","volume":"21","author":"JA Cramer","year":"2005","unstructured":"Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453\u20131460","journal-title":"Curr Med Res Opin"},{"key":"85_CR17","unstructured":"Recker RR, Gilmore A, Hebborn A, Takemoto S (2005) Bisphosphonate dosing regimens influence adherence to treatment in women with postmenopausal osteoporosis. Presented at the 87th Annual Meeting of the Endocrine Society, June 4\u20137, 2005, San Diego CA, abstract P3\u2013P372"},{"key":"85_CR18","unstructured":"Boccuzzi SJ, Foltz SH, Omar MA, Kahler KH (2005) Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Presented at the 87th Annual Meeting of the Endocrine Society, June 4\u20137, 2005, San Diego CA, abstract P1\u2013P438"},{"key":"85_CR19","doi-asserted-by":"crossref","first-page":"488","DOI":"10.18553\/jmcp.1998.4.5.488","volume":"4","author":"B Ettinger","year":"1998","unstructured":"Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N (1998) Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Managed Care Pharm 4:488\u2013492","journal-title":"J Managed Care Pharm"},{"key":"85_CR20","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s00198-003-1431-2","volume":"14","author":"A Papaioannou","year":"2003","unstructured":"Papaioannou A, Ioannidis G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M, Brown J, Tenenhouse A, Olszynski WP, Boulos P, Hanley DA, Josse R, Murray TM, Petrie A, Goldsmith CH (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808\u2013813","journal-title":"Osteoporos Int"},{"key":"85_CR21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","volume":"115","author":"AN Tosteson","year":"2003","unstructured":"Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209\u2013216","journal-title":"Am J Med"},{"key":"85_CR22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s001980170099","volume":"12","author":"A Pressman","year":"2001","unstructured":"Pressman A, Forsyth B, Ettinger B, Tosteson AN (2001) Initiation of osteoporosis treatment after bone mineral density testing. Osteoporos Int 12:337\u2013342","journal-title":"Osteoporos Int"},{"key":"85_CR23","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1464-5491.2005.01704.x","volume":"22","author":"AJ Karter","year":"2005","unstructured":"Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM (2005) Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 22:986\u2013993","journal-title":"Diabet Med"},{"issue":"Suppl 1","key":"85_CR24","first-page":"S286","volume":"20","author":"S Silverman","year":"2005","unstructured":"Silverman S, Siris E, Abbott T, Barr C, Harris S, Rosen C (2005) Adherence to bisphosphonate therapy is associated with decreased nonvertebral osteoporotic fracture risk. J Bone Miner Res 20(Suppl 1):S286 (abstract SU417)","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-006-0085-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-006-0085-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-006-0085-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T15:04:00Z","timestamp":1558623840000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-006-0085-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,5,11]]}},"alternative-id":["85"],"URL":"https:\/\/doi.org\/10.1007\/s00198-006-0085-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,12]]}}}